Citadel Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $123M | Buy |
1,418,619
+1,265,297
| +825% | +$123M | 0.02% | 685 |
|
|
2025
Q4 | $16.4M | Buy |
153,322
+20,696
| +16% | +$2.2M | ﹤0.01% | 2605 |
|
|
2025
Q3 | $13.4M | Buy |
+132,626
| New | +$12.3M | ﹤0.01% | 2842 |
|
|
2025
Q2 | – | Sell |
-70,068
| Closed | -$4.29M | – | 14725 |
|
|
2025
Q1 | $3.71M | Buy |
70,068
+29,649
| +73% | +$1.64M | ﹤0.01% | 4385 |
|
|
2024
Q4 | $2.26M | Sell |
40,419
-62,359
| -61% | -$3.44M | ﹤0.01% | 5373 |
|
|
2024
Q3 | $5.38M | Buy |
+102,778
| New | +$4.92M | ﹤0.01% | 3824 |
|
|
2024
Q2 | – | Sell |
-4,098
| Closed | -$164K | – | 15245 |
|
|
2024
Q1 | $178K | Sell |
4,098
-109,817
| -96% | -$4.81M | ﹤0.01% | 10517 |
|
|
2023
Q4 | $5.24M | Sell |
113,915
-141,518
| -55% | -$4.46M | ﹤0.01% | 3713 |
|
|
2023
Q3 | $5.86M | Buy |
255,433
+65,901
| +35% | +$1.48M | ﹤0.01% | 3407 |
|
|
2023
Q2 | $3.13M | Sell |
189,532
-175,508
| -48% | -$3.17M | ﹤0.01% | 4393 |
|
|
2023
Q1 | $6.51M | Buy |
365,040
+294,342
| +416% | +$7.39M | ﹤0.01% | 3388 |
|
|
2022
Q4 | $2.06M | Buy |
70,698
+14,863
| +27% | +$382K | ﹤0.01% | 5426 |
|
|
2022
Q3 | $1.37M | Sell |
55,835
-112,223
| -67% | -$2.09M | ﹤0.01% | 6337 |
|
|
2022
Q2 | $698K | Sell |
168,058
-81,866
| -33% | -$448K | ﹤0.01% | 7880 |
|
|
2022
Q1 | $2.88M | Buy |
+249,924
| New | +$2.19M | ﹤0.01% | 5292 |
|
|
2021
Q3 | – | Sell |
-32,574
| Closed | -$497K | – | 14533 |
|
|
2021
Q2 | $638K | Sell |
32,574
-86,134
| -73% | -$1.79M | ﹤0.01% | 9469 |
|
|
2021
Q1 | $2.52M | Buy |
118,708
+40,662
| +52% | +$1.18M | ﹤0.01% | 5852 |
|
|
2020
Q4 | $2.32M | Buy |
78,046
+49,648
| +175% | +$1.26M | ﹤0.01% | 5049 |
|
|
2020
Q3 | $615K | Buy |
+28,398
| New | +$651K | ﹤0.01% | 6921 |
|
|
2020
Q2 | – | Sell |
-20,758
| Closed | -$316K | – | 10411 |
|
|
2020
Q1 | $316K | Buy |
+20,758
| New | +$372K | ﹤0.01% | 7246 |
|
|
2019
Q1 | – | Sell |
-14,521
| Closed | -$391K | – | 9789 |
|
|
2018
Q4 | $391K | Buy |
14,521
+671
| +5% | +$18.5K | ﹤0.01% | 6810 |
|
|
2018
Q3 | $404K | Sell |
13,850
-36,365
| -72% | -$1.15M | ﹤0.01% | 7055 |
|
|
2018
Q2 | $1.57M | Sell |
50,215
-4,084
| -8% | -$112K | ﹤0.01% | 4467 |
|
|
2018
Q1 | $1.08M | Sell |
54,299
-147,529
| -73% | -$3.92M | ﹤0.01% | 4699 |
|
|
2017
Q4 | $5.87M | Buy |
+201,828
| New | +$5.34M | ﹤0.01% | 2296 |
|
Other funds holding RYTM
RCM
BBA
VPM
VCM
PA
Citadel Advisors's RYTM Position: Q1 2026 in Review
Citadel Advisors increased its Rhythm Pharmaceuticals (RYTM) stake by 825% in Q1 2026, buying an estimated $123M and bringing the position to 1,418,619 shares worth $123M. The position accounts for 0.02% of the portfolio, ranked #685.
Citadel Advisors first reported a position in RYTM in Q4 2017 and has held it in 25 quarters since. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.
- Citadel Advisors held 1,418,619 shares of Rhythm Pharmaceuticals worth $123M as of Q1 2026.
- Citadel Advisors bought 1,265,297 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $123M.
- Rhythm Pharmaceuticals made up 0.02% of Citadel Advisors's portfolio in Q1 2026, its #685 holding.
- Citadel Advisors first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 25 quarters since.
- 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.